Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
2,566 JPY | +2.23% | +3.26% | -9.36% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the past year, analysts have regularly revised upwards their sales forecast for the company.
- Upward revisions of sales forecast reflect a renewed optimism among the analysts covering the stock.
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the last 4 months, the company has been enjoying highly positive EPS revisions, which were frequently and significantly raised.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Over the past four months, analysts' average price target has been revised upwards significantly.
Ratings chart - Surperformance
Sector: Biotechnology & Medical Research
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-9.36% | 795M | - | ||
+1.77% | 42.75B | B | ||
+47.70% | 41.61B | A | ||
+12.24% | 41.34B | B- | ||
-8.83% | 26.59B | C | ||
+7.44% | 25.49B | B- | ||
-23.01% | 18.12B | B | ||
+30.56% | 12.24B | C+ | ||
-1.82% | 11.76B | C+ | ||
+8.35% | 11B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 2160 Stock
- Ratings GNI Group Ltd.